Madrigal Pharmaceuticals, based in Conshohocken, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with a significant unmet medical need. Their lead clinical candidate, resmetirom, is currently undergoing studies for the treatment of patients with NASH who have significant liver fibrosis or compensated cirrhosis.
With a focus on improving care for individuals affected by NASH, Madrigal Pharmaceuticals aims to address the lack of FDA-approved treatments for this condition through their research and development efforts. Their commitment to advancing novel therapies underscores their mission to make a meaningful impact on the lives of patients with NASH.
Generated from the website